DDR1 depletion inhibits cell growth and cell cycle progression and enhances the sensitivity of PIK3CA/AKT1 mutant cells to palbociclib in estrogen receptor (ER)-positive, HER2-negative breast cancer [33]. This evidence concerns the gene ESR1 and breast carcinoma.